Our microarray results demonstrated that at least 127 genes were differentially expressed in the bvrR mutant.
Our microarray results demonstrated several genes directly involved in cell envelope or outer membrane biogenesis differentially expressed in the bvrR mutant.
Our microarray results demonstrate that rosiglitazone does not reverse many of the significant gene expression and pathway changes that occur in untreated diabetic hearts, such as apoptosis and lipid metabolism.
In this respect, our inability to validate some of our discordant microarray results demonstrates that clearly other factors exist.
Similarly, our microarray results demonstrated a 2.8-fold increase in transcript level of X-linked G glucose-6-phosphate dehydrogenase (G6pdx), an enzyme involved in the first step of pentose phosphate pathway (PPP).
Nonetheless, microarray results demonstrated slight downregulation of TLR2, TLR4, TLR5, and TLR8, together with slight upregulation of MyD88, a key adaptor for these TLRs [ 82], in CD16+ compared to CD16- Mo We demonstrated increased expression of RARA mRNA in CD16+ compared to CD16- Mo.
Although the microarray assay results demonstrated more HrpL-downregulated genes than those upregulated by HrpL (Table 1, 2; Supplementary Fig. S2), none of the HrpL-downregulated genes had a hrp box HMM prediction with a high confidence level (Table 2; Supplementary Table S4; Supplementary Fig. S2H-I).
The proteomics assessment validates the microarray results in demonstrating that for those responses detected in CLI protocols, two leaves are sufficient to elicit most proteome changes.
These results were concordant with the microarray results and demonstrated the absence of the long transcript in mature blood cells.
With the exception of C3, qRT-PCR analysis of 7 of these genes confirmed the microarray results and demonstrated that GAPDH is not a suitable housekeeping gene in LPS challenged sheep.
